

PURSuing A RAPID PATH TO MARKET

The U.S. FDA has granted Breakthrough Therapy Designation and Orphan Drug Designation to gildeuretinol (ALK-001) for the treatment of Stargardt disease. Alkeus is engaged in discussions with regulatory authorities to define the most appropriate path to bring gildeuretinol to Stargardt disease patients as rapidly as possible. Alkeus plans to submit an NDA for approval of gildeuretinol in Stargardt disease in 2024.